08 Jan 24
London, U.K. 8th January 2024: tranScrip, the leading contract drug development organisation, announces that Mark Corbett has been named Chief Executive Officer (“CEO”) with effect from 01 January 2024. Mark has a wealth of experience within the pharmaceutical and pharmaceutical services industries, including senior commercial roles with respected organisations such as Inceptua, Clinigen, Idis and Servier.
Prior to joining tranScrip, Mark was Chief Innovation Officer and Executive Board member at Resonant Group, a privately owned group of agencies, where he led the Origins business while establishing a portfolio of potential value-enhancing opportunities.
Mark’s commercial and business leadership experience, will help tranScrip continue to develop and grow as a trusted partner for the pharmaceutical and biotech industry, and help make a real difference to the lives of patients.
Paul McCluskey, tranScrip’s Chairman, said:
“We are pleased to welcome Mark Corbett to our leadership team, bringing both commercial and pharmaceutical industry expertise that will spearhead our business development efforts in the next phase of our growth plan. With Mark’s guidance and expertise we anticipate the continued expansion of the business, fostering collaborations with our valued clients to deliver innovative solutions. We will strive to ensure the secure and efficient market entry of new medicines, ultimately enhancing patients’ lives globally.”
Mark Corbett, tranScrip’s CEO, said:
“I am excited to join tranScrip at this crucial point in the business’s growth journey. tranScrip has a compelling business proposition to offer strategic expertise and operational support throughout the entire life-cycle of medicines, medical devices and combination products. It has a long-established reputation for bringing the highest quality of support to pharma and biotech companies. I look forward to getting to know the team, the board and our clients, as we continue to grow our presence as a trusted partner for companies wishing to master the complexities of drug development, regulatory approval and commercial success. Together, we will continue to build on tranScrip’s industry-leading position to help our clients realise the full potential of their innovation as efficiently as possible and help deliver life changing products for patients.”
We have teams of life science and R&D experts to help achieve your goals and seize opportunities. Whatever your project requires, we have the people to meet your needs.